We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Zealand Pharma AS (ZEAL) DKK1

Sell:655.50 DKK Buy:657.00 DKK Change: 16.50 DKK (2.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:655.50 DKK
Buy:657.00 DKK
Change: 16.50 DKK (2.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:655.50 DKK
Buy:657.00 DKK
Change: 16.50 DKK (2.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Contact details

Sydmarken 11
+45 () 88773600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
40.10 billion DKK
Shares in issue:
62.30 million
Copenhagen Stock Exchange
Danish Krone

Key personnel

  • Adam Steensberg
    President, Chief Executive Officer, Member of the Executive Management
  • Henriette Wennicke
    Executive Vice President, Chief Financial Officer, Member of the Executive Management
  • Ivan Moeller
    Executive Vice President, Chief Operating Officer
  • Christina Bredal
    Chief People Officer, Executive Vice President
  • Ravinder Singh Chahil
    Senior Vice President, General Counsel
  • David Kendall
    Chief Medical Officer, Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.